(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, will be attending and/or presenting at the following conferences in the first half of 2017 in US.
- 0 Comments
- FY2017